American Capital Advisory LLC Buys 614 Shares of Pfizer Inc. (NYSE:PFE)

American Capital Advisory LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 31.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,582 shares of the biopharmaceutical company’s stock after acquiring an additional 614 shares during the quarter. American Capital Advisory LLC’s holdings in Pfizer were worth $75,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in PFE. China Universal Asset Management Co. Ltd. bought a new stake in Pfizer in the first quarter worth $315,000. Central Pacific Bank Trust Division bought a new position in shares of Pfizer during the first quarter valued at $136,000. GSA Capital Partners LLP bought a new position in shares of Pfizer during the first quarter valued at $439,000. Disciplined Equity Management Inc. lifted its holdings in shares of Pfizer by 2,676.8% during the first quarter. Disciplined Equity Management Inc. now owns 66,920 shares of the biopharmaceutical company’s stock valued at $1,857,000 after purchasing an additional 64,510 shares in the last quarter. Finally, Broderick Brian C lifted its holdings in shares of Pfizer by 382.9% during the first quarter. Broderick Brian C now owns 34,550 shares of the biopharmaceutical company’s stock valued at $959,000 after purchasing an additional 27,396 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

PFE traded down $0.68 during midday trading on Wednesday, reaching $27.31. The company had a trading volume of 21,969,490 shares, compared to its average volume of 37,226,355. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average of $28.99 and a two-hundred day moving average of $28.65. The company has a market cap of $154.76 billion, a P/E ratio of 37.81, a P/E/G ratio of 0.89 and a beta of 0.67. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The business’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.17) earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.15%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Citigroup assumed coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Barclays upped their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.